Compare GSK plc (GSK) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs SYSCO Corporation — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while SYSCO Corporation trades at $78.1 (market cap $38.47B). The key difference: GSK plc is far larger — about 2.4× SYSCO Corporation's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and SYSCO Corporation for 77 Days on average.
| GSK | SYY | |
|---|---|---|
Market Cap | $91.88B | $38.47B |
Volume | 7,730,529 | 4,808,465 |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $91.16 |
52-Week Low | $43.24 | $69.30 |
Typical Hold Time | 93 Days | 77 Days |
Enterprise Value | $111.88B | $51.65B |
Dividend Yield | 3.9% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
SYY trades at $78.31, up 1.98% today, with a neutral technical signal and mixed earnings history. The company reported revenue growth to $81.37B in 2025, though net income margin dipped to 2.08%. Recent news highlights a $500M AI efficiency program and a $1.5B senior notes offering, signaling strategic investments. Analyst consensus is bullish with a $85.75 price target, but the stock faces headwinds from high debt levels and competitive pressures.
The outlook for SYY is cautiously optimistic, supported by steady revenue growth and a strong analyst buy rating. Key opportunities include AI-driven cost savings and market expansion, while risks involve elevated leverage and margin compression. Investors should weigh the potential for earnings acceleration against macroeconomic sensitivity in the consumer staples sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
